Citations

Mayo Clinic

Clear

2153 citation(s) found for "Ma, Anna".

The Modifying Effects of Sex, Race, and Social Relationships on the Association between White Matter Integrity and Dementia Risk: The Atherosclerosis Risk in Communities (ARIC) Neurocognitive Study
Eswaran, Surabhee, Gottesman, Rebecca F., Liu, Albert C. , Palta, Priya, Sharrett, A. Richey, Groechel, Renee, Knopman, David S. , Koton, Silvia , Kucharska‐Newton, Anna , Liu, Chelsea , Lutsey, Pamela L. , Mosley, Thomas H. , Sullivan, Kevin , Walker, Keenan A. , Groechel, Renée C.

Alzheimer's & Dementia | January 9, 2025 | Volume: 20 | Issue: S7 | Pages: No page available

10.1002/alz.087094 Get It

AbstractBackgroundWeakened white matter (WM) integrity is highly associated with dementia risk. Still, not everyone with WM changes develops dementia, suggesting the important role modifiable lifestyle factors may have in reducing dementia risk. We investigated how social relationships in mid‐life may modify the association between WM integrity and incident dementia risk within race and sex subgroups.MethodIn 1,679 Atherosclerosis Risk in Community (ARIC) study participants who were dementia‐free in mid‐life, psychosocial health was assessed via self‐reported questionnaires and participants were classified as having strong or poor social relationships in mid‐life (visit 2: 1990‐1992). Through diffusion tensor imaging, WM integrity was evaluated with 3T brain MRI (visit 5: 2011 – 2013); fractional anisotropy (FA) and mean diffusivity (MD) were estimated. Incident dementia cases were identified from visit 5 through December 31, 2019, with ongoing surveillance. Relative contributions of social relationships and WM integrity to incident dementia were evaluated in Cox‐proportional hazard regression models with race and race‐sex as interaction terms, and in stratified models (White Females, Black Females, White Males, Black Males).ResultSignificant three‐way interactions were observed between race, WM integrity, and mid‐life social relationships (p‐interaction<0.01). In Black participants with strong mid‐life social relationships, higher MD (hazard ratio (HR): 0.93, 95% CI: 0.63 – 1.38) and lower FA (HR: 1.25, 95% CI: 0.84 – 1.86) were not associated with the risk of dementia, although in Black participants with poor social relationships, higher MD remained a significant risk factor for dementia. However, across all White participants, higher MD and lower FA were associated with the risk of dementia, regardless of mid‐life social relationships (Table 1; Figure 1). Analysis of three‐way interactions between race‐sex, WM integrity, and mid‐life social relationships suggested that effect modification by mid‐life social relationships was most evident in Black Females, respective to other groups (Table 2; Figure 1).ConclusionThe contribution of WM integrity to dementia risk may be lower in Black participants with strong social relationships in mid‐life, particularly in Black Females. Further understanding of how contextual social factors may influence brain health in diverse populations should be examined in future studies and intervention efforts.
The Modifying Effects of Sex, Race, and Social Relationships on the Association between White Matter Integrity and Dementia Risk: The Atherosclerosis Risk in Communities (ARIC) Neurocognitive Study
Eswaran, Surabhee, Liu, Albert C. , Palta, Priya, Sharrett, A. Richey , Groechel, Renee, Gottesman, Rebecca F. , Knopman, David S. , Koton, Silvia , Kucharska‐Newton, Anna , Liu, Chelsea , Lutsey, Pamela L. , Mosley, Thomas H. , Sullivan, Kevin , Walker, Keenan A. , Groechel, Renée C.

Alzheimer's & Dementia | January 9, 2025 | Volume: 20 | Issue: S9 | Pages: No page available

10.1002/alz.093711 Get It

AbstractBackgroundWeakened white matter (WM) integrity is highly associated with dementia risk. Still, not everyone with WM changes develops dementia, suggesting the important role modifiable lifestyle factors may have in reducing dementia risk. We investigated how social relationships in mid‐life may modify the association between WM integrity and incident dementia risk within race and sex subgroups.MethodIn 1,679 Atherosclerosis Risk in Community (ARIC) study participants who were dementia‐free in mid‐life, psychosocial health was assessed via self‐reported questionnaires and participants were classified as having strong or poor social relationships in mid‐life (visit 2: 1990‐1992). Through diffusion tensor imaging, WM integrity was evaluated with 3T brain MRI (visit 5: 2011 – 2013); fractional anisotropy (FA) and mean diffusivity (MD) were estimated. Incident dementia cases were identified from visit 5 through December 31, 2019, with ongoing surveillance. Relative contributions of social relationships and WM integrity to incident dementia were evaluated in Cox‐proportional hazard regression models with race and race‐sex as interaction terms, and in stratified models (White Females, Black Females, White Males, Black Males).ResultSignificant three‐way interactions were observed between race, WM integrity, and mid‐life social relationships (p‐interaction<0.01). In Black participants with strong mid‐life social relationships, higher MD (hazard ratio (HR): 0.93, 95% CI: 0.63 – 1.38) and lower FA (HR: 1.25, 95% CI: 0.84 – 1.86) were not associated with the risk of dementia, although in Black participants with poor social relationships, higher MD remained a significant risk factor for dementia. However, across all White participants, higher MD and lower FA were associated with the risk of dementia, regardless of mid‐life social relationships (Table 1; Figure 1). Analysis of three‐way interactions between race‐sex, WM integrity, and mid‐life social relationships suggested that effect modification by mid‐life social relationships was most evident in Black Females, respective to other groups (Table 2; Figure 1).ConclusionThe contribution of WM integrity to dementia risk may be lower in Black participants with strong social relationships in mid‐life, particularly in Black Females. Further understanding of how contextual social factors may influence brain health in diverse populations should be examined in future studies and intervention efforts.
Developing a novel claim‐based algorithm to identify incident and prevalent dementia using Medicare claims of the Atherosclerosis Risk in Communities (ARIC) cohort
Pate, Virginia , Palta, Priya, Jonson‐Funk, Michelle , Wang, Tiansheng , Kim, Dae Hyun , Power, Melinda C. , Garden, Gwenn A. , Knopman, David S. , Stürmer, Til , Kucharska‐Newton, Anna

Alzheimer's & Dementia | January 9, 2025 | Volume: 20 | Issue: S6 | Pages: No page available

10.1002/alz.089988 Get It

AbstractBackgroundPharmacoepidemiologic studies assessing drug effectiveness for Alzheimer’s disease and related dementias (ADRD) are increasingly popular given the critical need for effective therapies for ADRD. To meet the urgent need for robust dementia ascertainment from real‐world data, we aimed to develop a novel algorithm for identifying incident and prevalent dementia in claims.MethodWe developed algorithm candidates by different timing/frequency of dementia diagnosis/treatment to identify dementia from inpatient/outpatient/prescription claims for 6,515 and 3,997 participants from Visits 5 (2011‐2013; mean age 75.8 (SD 5.3) years) and 6 (2016‐2017; mean age 79.8 (SD 4.8) years) of the ARIC cohort with ≥ 1‐year continuous Medicare Part A & B enrollment prior to each visit. We evaluated algorithm performance (sensitivity/specificity/positive predictive value (PPV)/negative predictive value (NPV)) against the gold standard of the ARIC dementia classification based on an extensive battery of neurocognitive tests administered at each visit. We compared performance of the new algorithm with that of three existing algorithms (Jain, Bynum, Lee) and their relaxed forms (4‐year window, dementia diagnosis plus a depression diagnosis or dementia evaluation procedure, ignoring code position) to identify incident (n = 90 at V6) and prevalent dementia (n = 190 at V5; n = 160 at V6).ResultThe newly developed primary algorithm requires presence of a dementia diagnosis code followed by another diagnosis code within 1 year (under condition that the following non‐specific ICD‐9 diagnostic codes, 290.40, 290.41, 290.11, 290.3, should appear no more than once), or a subsequent dementia treatment prescription within 90 days (requiring Medicare Part D enrollment ≥ 6 months). The PPV of the new algorithm in the identification of incident dementia was PPV of 72.7%, with a specificity of 99.1%, outperforming existing algorithms. Its sensitivity of 38.7% and NPV of 96.2% were comparable to those achieved by existing algorithms. Sensitivity analysis restricting to ICD‐10 diagnostic codes increased the PPV and attenuated its sensitivity by 6%. Similar comparative performance was observed in the identification of prevalent dementia.ConclusionA novel algorithm for identifying dementia from Medicare claims, developed using linked ARIC‐Medicare data, outperforms previous algorithms and stands as a valuable tool in the assessment of ADRD drugs from real‐world data.
Prevalence and Risk Factors of Spondyloarthritis Symptoms in a US-Based Multicenter Cohort of Patients With Inflammatory Bowel Disease
Hong, Simon , Dalal, Rahul S. , Kuhn, Kristine A. , Stahly, Andrew , Scott, Frank I. , Click, Benjamin , Way, Anna, Malik, Fardina , Davis, John M. , Shmais, Manar , Raffals, Laura E., Silfen, Alexa , Dharia, Ishaan , Bhattacharya, Ashish K. , Moghaddam, Bahar, Mains, Trayton, Kurland, Jayde E., Hong, Simon J , Click, Benjamin H , Rubin, David T , Bhattacharya, Abhik , Ermann, Joerg , Jan, Reem , Davis, John M , Silfen, Alexa , Kuhn, Kristine A , Scott, Frank I , Way, Anna, Raffals, Laura E. , Rubin, David T. , Patel, Sheena , Weisman, Michael H. , Ermann, Joerg

American Journal of Gastroenterology | January 6, 2025 | Volume: 120 | Issue: 10 | Pages: 2330-2338

10.14309/ajg.0000000000003292 | PMID 39760386 Get It

INTRODUCTION: Spondyloarthritis (SpA), the most common extraintestinal manifestation of inflammatory bowel disease (IBD), is reported in up to 39% of patients with IBD. Despite this high prevalence, risk factors of developing SpA in patients with IBD are not well described. In this study, we aimed to determine the factors associated with SpA symptoms and their prevalence in an IBD cohort. METHODS: Two validated screening questionnaires for the detection of SpA in IBD (DETAIL = DETection of Arthritis in Inflammatory boweL diseases, IBIS-Q = IBD Identification of Spondyloarthritis Questionnaire) were administered to patients with IBD without a prior diagnosis of SpA in 6 US academic medical centers. Demographic data, IBD characteristics, and medication history were recorded. RESULTS: Screening questionnaires were completed by 588 patients (220 ulcerative colitis, 349 Crohn's disease, and 19 IBD-unclassified), with a median age of 40 years (interquartile range 30–53) and median disease duration of 12 years (interquartile range 6–22). The number of positive screens was 130 (22%) for DETAIL, 196 (33%) for IBIS-Q, and 204 (35%) for either DETAIL or IBIS-Q. Age, female sex, history of smoking, prior bowel surgery, and history of any biologic or targeted small molecule exposure were associated with a positive screen on univariate analysis. After multivariate analysis, female sex (odds ratio [OR] 2.03, 95% confidence interval [CI] 1.41–2.93), older age (OR 1.02, 95% CI 1.01–1.04), history of smoking (OR 1.67, 95% CI 1.04–2.69), and history of any biologic or targeted small molecule exposure (OR 2.27, 95% CI 1.34–3.84) were independently associated with positive screens. Higher number of biologic exposures was associated with higher risk of positive screens, with the highest risk seen with 3 or more exposures (OR 3.25, 95% CI 1.75–6.03). DISCUSSION: A substantial number of patients with IBD screen positive for SpA symptoms, indicating a potentially high burden of undiagnosed illness. Factors associated with SpA symptoms include older age, female sex, and more severe disease (based on increased number of advanced therapies or prior surgery), whereas IBD phenotype does not independently increase the risk of a positive SpA screen. Further studies are needed to confirm these findings and better characterize SpA in IBD.
Ethical Use of Cadaveric Images in Anatomical Textbooks, Atlases, and Journals: A Consensus Response From Authors and Editors
Kim, Hee‐Jin , Logan, Bari M., Hutchings, R. T., Anand, Mahindra , Burns, Danny, Singh, Vishram, Peris‐Celda, Maria , Martı́nez-Soriano, Francisco, Apaydın, Nihal, Hanna, Amgad S. , Yoshioka, Nobutaka , Fernandez‐Miranda, Juan C. , Saremi, Farhood , Spratt, Jonathan D., Ho, Siew Yen , Mori, Shumpei , Komune, Noritaka , Watanabe, Koichi , Abrahams, Peter, Ibaragi, Soichiro , Loukas, Marios , Tubbs, R. Shane, Kim, Hee-Jin , Hur, Mi-Sun , Reina, Francisco , Tabira, Yoko , Carrera, Anna , Komune, Noritaka , Watanabe, Koichi , Reina, Miguel Angel , Loukas, Marios , Iwanaga, Joe , Akita, Keiichi , Ottone, Nicolás Ernesto , Nonaka, Yoichi , Shoja, Mohammadali M. , Tabira, Yoko , Prats‐Galino, Alberto , Andrés, José De , Reina, Miguel Ángel , Anderson, Robert Henry

Clinical Anatomy | January 4, 2025 | Volume: 38 | Issue: 2 | Pages: 222-225

10.1002/ca.24258 | PMID 39754475 Get It

ABSTRACT Nowadays, consent to use donor bodies for medical education and research is obtained from the body donors and their families before the donation. Recently, the International Federation of Associations of Anatomists (IFAA) published guidelines that could restrict the appearance of cadaveric images in commercial anatomical resources such as textbooks and other educational products. These guidelines state that the donor must expressly consent to using such images for this purpose. Cadaveric photos and drawings made from dissections of cadavers have been used in anatomy textbooks and atlases for hundreds of years. They are invaluable for anatomy students and clinical/surgical practitioners. The IFAA guidelines should not restrict the use of those older books; to do so would infringe the rights of those seeking knowledge from these resources. As the images in such textbooks and atlases are anonymized and are used for teaching and research, and the donors and their families are informed about this before the donation, we believe no additional consent is needed. It is impossible to separate educational from “commercial” usage entirely in any situation, e.g., publications from publishers and the use of cadavers in medical schools. Therefore, our best efforts to avoid unethical use of cadaveric images by following traditional consent processes are still needed so that more people will reap the benefits from them. As senior textbook/atlas authors/editors from over 10 countries, we believe that using cadaveric images in anatomy textbooks is appropriate, and no additional consent should be necessary. Such usage falls within the good faith of professionals using these invaluable gifts.
Multi‐omics profiling of Alzheimer’s disease in multi‐ethnic populations
Reddy, Joseph S. , Allen, Mariet , Poehlman, William L. , Wang, Yanling , Johnson, Ryan , Ho, Charlotte C.G. , Linden, Abby Vander , Quicksall, Zachary , Chen, Xianfeng , Baheti, Saurabh , Nguyen, Thuy , Yepez‐Sisalema, Geovanna, Mitchell, Adriana O., Oatman, Stephanie R., Wang, Xue , Carrasquillo, Minerva M. , Beach, Thomas G., Golde, Todd E. , Haroutunian, Vahram , Jager, Philip L. De , Bennett, David A. , Seyfried, Nicholas T. , Ertekin‐Taner, Nilüfer , Initiative, Accelerating Medicines Partnership for Alzheimer’s Disease (AMP‐AD) Diversity, Heath, Laura , Johnson, Ryan, Wang, Erming , Ma, Yiyi , Lopes, Kátia de Paiva , Wang, Xue, Carrasquillo, Minerva M. , Runnels, Alexi , Teich, Andrew F. , Beach, Thomas G. , Serrano, Geidy E. , Barnes, Lisa L. , Wang, Minghui , Zhang, Bin , Greenwood, Anna, Initiative, Accelerating Medicines Partnership for Alzheimer’s Disease (AMP‐AD) Diversity

Alzheimer's & Dementia | January 3, 2025 | Volume: 20 | Issue: S1 | Pages: No page available

10.1002/alz.090590 Get It

AbstractBackgroundAlzheimer’s disease (AD) is a devastating neurodegenerative disorder with few therapies to treat, mitigate or prevent its onset. Understanding of this disease is predominantly based on research in non‐Hispanic Whites (NHW) although AD disproportionately affects African Americans (AA) and Latin Americans (LA), underrepresented in AD research. To address this knowledge gap, the Accelerating Medicine Partnership for Alzheimer’s Disease (AMP‐AD) Diversity Working Group was launched to generate multi‐omics data from post‐mortem brain tissue from donors of predominantly AA and LA descent. Here, we focus on genomic and transcriptomics measures, made available through the AD Knowledge Portal (ADKP).MethodBrain tissue from dorsolateral prefrontal cortex (DLPFC), caudate nucleus (CN), superior temporal gyrus (STG) and temporal pole (TP) regions of AA (N = 299), LA (N = 344) and NHW (N = 532) donors was obtained through Mayo Clinic, Mt. Sinai School of Medicine, Emory, Columbia, Rush Alzheimer’s Disease Center, Banner Sun Health, and 1Florida. DNA extracted from DLPFC tissue samples (n = 641) was utilized for whole genome sequencing (WGS) at New York Genome Center (NYGC). RNAseq of 2,224 samples was conducted either at Mayo, Rush or NYGC. Sequencing reads were processed through GenomeGPS and MAPRseq pipelines for WGS and RNAseq data, respectively. Following quality control (QC), RNAseq data was normalized and assessed for sources of variation (SOV). Integration of WGS and RNAseq data to perform comparative eQTL analysis across multi‐ethnic populations and brain regions is ongoing.ResultWGS data for 621 donors, and RNAseq data generated at Mayo (n = 1,136 samples), Rush (n = 627), and NYGC (n = 779) sequencing centers, were deposited to the ADKP. Consensus processing of RNAseq data revealed site, sex, race/ethnicity, RIN, AD diagnosis, age at death and/or library batch as SOV across various sites and brain regions. Principal component analysis of gene expression measures revealed no major stratification by disease or brain region. Accompanying clinical metadata of donors have been distributed through ADKP.ConclusionThese multi‐omics data made available to the research community is expected to be an initial step towards bridging our data and knowledge gap to elucidate conserved and distinct AD related pathways across these underrepresented at‐risk populations.
Functional connectivity associations with markers of disease progression in GRN mutation carriers
Flagan, Taru , Chu, Stephanie A. , Häkkinen, Suvi , Zhang, Liwen , McFall, David , Heller, Carolin , Rohrer, Jonathan D., Brown, Jesse A. , Fernhoff, Kristen, Mandelli, Maria Luisa , Tempini, Maria Luisa Gorno , Sturm, Virginia E. , Dickerson, Brad C., Foroud, Tatiana M., Geschwind, Daniel H. , Ghoshal, Nupur , Graff‐Radford, Neill R. , Huey, Edward D. , Karydas, Anna M., Kaufer, Daniel , Mackenzie, Ian R. , Mendez, Mario F. , Onyike, Chiadi U. , Petrucelli, Leonard , Ramos, Eliana Marisa , Weıntraub, Sandra , Forsberg, Leah K. , Heuer, Hilary W. , Boxer, Adam L. , Rosen, Howard J. , Lee, Suzee E. , Consortia, the ARTFL/LEFFTDS, Rohrer, Jonathan D. , Lee, Alex J. , Pasquini, Lorenzo , Yokoyama, Jennifer S. , Appleby, Brian S. , Domoto‐Reilly, Kimiko , Grossman, Murray , Hsiung, Ging‐Yuek Robin , Huang, Eric J. , Kantarci, Kejal , Knopman, David S. , Litvan, Irene , Roberson, Erik D. , Rojas, Julio C. , Tartaglia, Maria Carmela , Toga, Arthur W. , Boeve, Bradley F. , Miller, Bruce L. , Moreno, Fermín , Seeley, William W. , Consortia, the ARTFL/LEFFTDS

Alzheimer's & Dementia | January 3, 2025 | Volume: 20 | Issue: S1 | Pages: No page available

10.1002/alz.087301 Get It

AbstractBackgroundAutosomal dominant progranulin (GRN) mutations are a common genetic cause of frontotemporal lobar degeneration. Though clinical trials for GRN‐related therapies are underway, there is an unmet need for biomarkers that can predict symptom onset and track disease progression. We previously showed that presymptomatic GRN carriers exhibit thalamocortical hyperconnectivity that increases with age when they are presumably closer to symptom onset. However, whether hyperconnectivity arises concomitantly with markers of neurodegeneration remains unclear.MethodUtilizing T1 and task‐free functional magnetic resonance imaging (tf‐fMRI) from 49 presymptomatic and 26 symptomatic GRN mutation carriers, we determined the relationships between functional connectivity as measured by voxel‐wise whole brain degree and GRN‐relevant markers of disease progression, which included plasma neurofilament light chain (NfL) concentrations, CSF complement C1q and C3b protein levels, grey matter atrophy, and OCD symptom severity.ResultNfL concentrations were associated with frontotemporoparietal and thalamic hyperconnectivity in presymptomatic GRN carriers and extensive regions of atrophy in symptomatic carriers. Complement levels were associated with regions of hyperconnectivity, but not gray matter, in symptomatic carriers. Presymptomatic carriers with thalamic hyperconnectivity tended to have lower grey matter volume in bilateral insula and left lateral parietal cortex, which are among regions that deteriorate in GRN‐FTD. OCD symptom severity was associated with hypoconnectivity across all GRN carriers.ConclusionIn presymptomatic carriers, the co‐occurrence of hyperconnectivity, high NfL, and low gray matter suggests that tf‐fMRI hyperconnectivity may portend the onset of the neurodegenerative phase. These findings point toward hyperconnectivity as an indicator of approaching symptomatic onset.
Sex differences in familial forms of frontotemporal dementia
Memel, Molly B, Staffaroni, Adam M. , Kornak, John , Cadwallader, Claire J. , Chen, Coty , Heuer, Hilary W. , Forsberg, Leah K. , Boxer, Adam L., Rosen, Howard J., Casaletto, Kaitlin B. , Illán‐Gala, Ignacio , Saloner, Rowan , VandeBunte, Anna M. , Paolillo, Emily W. , Gendron, Tania F. , Boeve, Bradley F. , Boxer, Adam L.

Alzheimer's & Dementia | January 3, 2025 | Volume: 20 | Issue: S3 | Pages: No page available

10.1002/alz.092552 Get It

AbstractBackgroundSex differences in neurodegenerative diseases can impact accurate diagnosis and management. Emerging data suggest there may be sex differences in frontotemporal dementia (FTD) prevalence and clinical manifestation. However, prior studies lacked longitudinal assessment and were limited in capturing sex differences in earliest stages of disease (e.g., preclinical). We evaluated how sex impacts longitudinal clinical outcomes in individuals carrying autosomal dominant variants for FTD.Method337 participants carrying pathogenic variants in MAPT, GRN, or C9orf72 completed longitudinal evaluations (2.4 average visits, range = 1‐6), including neuropsychological and functional assessments, and plasma analyzed for neurofilament light chain (NfL). FTLD Clinical Dementia Rating Scale (FTLD‐CDR) classified disease stage at study entry (FTLD‐CDR = 0: asymptomatic; FTLD‐CDR = 0.5: MCI; FTLD‐CDR> 0.5: Dementia). Linear mixed‐effects models evaluated the effect of sex on longitudinal clinical trajectories, including the effect of disease stage at study entry.ResultMale and female carriers were similarly distributed with respect to baseline demographics and most clinical outcomes. However, women exhibited higher baseline NfL than men. Not accounting for disease stage, men and women did not show statistical differences on cognitive, functional, or NfL trajectories. However, when accounting for disease stage, there was a significant interaction between baseline disease stage, sex, and time on cognitive, NfL, and functional trajectories. While sex differences were not statistically significant among asymptomatic carriers, women with MCI/dementia evidenced more rapid cognitive, NfL and functional decline over time compared to men. To evaluate the role of pathology burden, we tested the interaction between baseline NfL, sex, and time on clinical outcomes stratified by disease stage. In asymptomatic participants, women showed an attenuated adverse relationship between baseline NfL and clinical trajectories compared to men. No statistically significant sex differences were evident in the relationship between baseline NfL and clinical outcomes in participants with MCI/dementia.ConclusionIn familial FTD, women evidenced steeper clinical declines than men after symptom onset. Accounting for pathology, baseline NfL was a stronger predictor of clinical decline in asymptomatic men compared to women. NfL may be a less sensitive prognostic tool for clinical progression in women with FTD, particularly early in disease. This may reflect early “cognitive resilience” to neurodegeneration in women.
Passively collected data from smartphones improves detection of frontotemporal dementia compared to the MoCA
Casaletto, Kaitlin B. , Taylor, Jack C. , Heuer, Hilary W. , Wise, Amy B. , Dhanam, Sreya, Palacios, Brandon R., Young, Jacob , Dutt, Shubir , Cadwallader, Claire J. , Kramer, Joel H. , Forsberg, Leah K. , Rosen, Howard J. , Boxer, Adam L. , Staffaroni, Adam M. , Paolillo, Emily W. , Dhanam, Sreya , Sanderson‐Cimino, Mark , Bui, Minh , Saloner, Rowan , VandeBunte, Anna M. , Kremers, Walter K. , Boeve, Bradley F.

Alzheimer's & Dementia | January 3, 2025 | Volume: 20 | Issue: S3 | Pages: No page available

10.1002/alz.090571 Get It

AbstractBackgroundFrontotemporal dementia (FTD) is a common young‐onset dementia. Challenges to in‐person FTD evaluations (e.g., behavioral symptoms, disease rarity), highlight the need to develop remote, low‐burden assessment techniques. A growing literature supports passive digital phenotyping for monitoring neurobehavioral change. Thus, we examined the utility of passively collected data from smartphones to detect prodromal or symptomatic FTD compared to that of the Montreal Cognitive Assessment (MoCA), a common cognitive screener.Method199 adults enrolled in the ALLFTD Mobile App study (mean age = 53.4 [SD = 15.2]; 58% women) completed up to 6 months of passive smartphone monitoring via the ALLFTD Mobile App. 55% were unimpaired [CDR®+NACC FTLD = 0], 22% had prodromal FTD [CDR®+NACC FTLD = 0.5], and 23% had symptomatic FTD [CDR®+NACC FTLD≥1] with a variety of syndromic presentations. Battery percentage was collected frequently (median interval = 45 min), and total daily battery usage was calculated as a proxy for smartphone use (higher battery usage = more smartphone use). Daily step counts were also passively collected. Logistic regression classified prodromal or symptomatic FTD vs. unimpaired as a function of: MoCA score [Model 1]; 7 passive features characterizing average, inter‐day variability, and changes over time in smartphone use and movement [Model 2]; or passive smartphone features and MoCA [Model 3]. Analyses were repeated excluding participants with symptomatic FTD to detect prodromal FTD vs. unimpaired.ResultThe area under the curves (AUCs) for detecting prodromal or symptomatic FTD (vs. unimpaired) from the MoCA alone [Model 1] and passive smartphone features alone [Model 2] were 0.77 (95%CI: 0.70‐0.85) and 0.77 (95%CI: 0.70‐0.84), respectively. Their combination [Model 3] resulted in a significantly improved AUC of 0.86 (95%CI: 0.80‐0.92) compared to Model 1 (p = 0.001). Significant Model 3 predictors included average daily battery usage (p = 0.02), slopes of change in step count (p = 0.04), and MoCA score (p<0.01). When distinguishing prodromal FTD from unimpaired, passive smartphone features alone (AUC = 0.75) were significantly better than the MoCA alone (AUC = 0.66; p<0.01), and their combination had the largest AUC (0.80).ConclusionResults support the utility of novel passively collected information from smartphones for detecting and monitoring FTD without contributing to assessment burden. With continued validation, passive digital monitoring methodologies have potential to increase access to dementia care.
Cognitive screening in the emergency department: Agreement between the patient‐ and caregiver‐completed AD8
Galske, James , Sather, Anna, Chera, Tonya, Gettel, Cameron J. , Hwang, Ula , Carpenter, Christopher R.

Alzheimer's & Dementia | January 3, 2025 | Volume: 20 | Issue: S3 | Pages: No page available

10.1002/alz.087105 Get It

AbstractBackgroundImpaired cognition is prevalent in older adults in the emergency department (ED), but many cases go unrecognized. The Ascertain Dementia 8 (AD8) is a validated, self‐administered screening tool that can be used by patients and caregivers to assess for early cognitive changes associated with dementia. However, little is known regarding the degree of alignment between respondents in the ED setting. Our objective was to assess the agreement between the patient‐(pAD8) versus caregiver‐completed AD8 (cAD8).MethodsWe conducted a prospective observational study of community‐dwelling older adults aged 65+ years seeking emergency care and their caregivers between October 2021 and November 2023. Patients with a diagnosis of dementia indicated in the electronic health record were excluded. Collected by trained research assistants, AD8 scores ranged from 0‐8, with scores 2+ indicating cognitive impairment. Patients and caregivers were blinded to the others’ AD8 rating. The intraclass correlation coefficient (ICC) was used to assess the agreement of the presence or absence of cognitive impairment based on pAD8 and cAD8 scores.ResultsOur analytic sample included 538 dyads, of which 34.7% of patients were male with a mean age of 73.5. A total of 132 (24.5%) patients scored themselves as cognitively impaired versus 201 (37.4%) patients were scored as cognitively impaired by their caregivers. Between groups, an ICC of 0.519 (95% CI 0.454‐0.578) demonstrated moderate agreement in identifying cognitive impairment based on pAD8 and cAD8 scores.ConclusionApproximately 1 in 4 older adults without a dementia diagnosis in the emergency department identified themselves as having cognitive impairment, with caregivers even more likely to identify cognitive impairment in accompanied older adult patients. With current guidance suggesting that the pAD8 be used in the absence of the cAD8, these findings highlight important differences to account for based on the respondent when screening for cognitive impairment.